ELOX ELOXX PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ELOXX PHARMACEUTICALS INC reported revenue of n/a, net income of −$4.50M and diluted EPS of −$0.66; for the fiscal year ended December 2025 revenue was $0, down 100.0% on the year before.
ELOX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$6.44M, net income −$6.00M (margin n/a), EPS −$5.34
- Fiscal year ended Dec 2024: revenue $6.36M, gross profit n/a, operating income −$2.47M, net income −$3.14M (margin -49.4%), EPS −$9.20
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$17.3M, net income −$17.1M (margin n/a), EPS −$72.98
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$34.4M, net income −$36.1M (margin n/a), EPS −$16.65
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$66.0M, net income −$66.7M (margin n/a), EPS −$38.15
ELOX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$4.50M, EPS −$0.66
- Quarter ended Mar 31, 2026: revenue n/a, net income −$3.75M, EPS −$0.86
- Quarter ended Jun 30, 2025: revenue n/a, net income −$1.89M, EPS −$5.45
- Quarter ended Mar 31, 2025: revenue n/a, net income −$1.71M, EPS −$4.94
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$2.89M, EPS −$66.83
- Quarter ended Sep 30, 2023: revenue n/a, net income −$3.59M, EPS −$1.31
- Quarter ended Jun 30, 2023: revenue n/a, net income −$4.34M, EPS −$1.96
- Quarter ended Mar 31, 2023: revenue n/a, net income −$6.23M, EPS −$2.88
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$6.32M, EPS −$2.92
- Quarter ended Sep 30, 2022: revenue n/a, net income −$7.51M, EPS −$3.47
- Quarter ended Jun 30, 2022: revenue n/a, net income −$10.6M, EPS −$4.90
- Quarter ended Mar 31, 2022: revenue n/a, net income −$11.6M, EPS −$5.36
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$12.1M, EPS −$37.28
- Quarter ended Sep 30, 2021: revenue n/a, net income −$9.89M, EPS −$0.11
- Quarter ended Jun 30, 2021: revenue n/a, net income −$36.1M, EPS −$0.54
- Quarter ended Mar 31, 2021: revenue n/a, net income −$8.69M, EPS −$0.22
ELOX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$6.33M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$4.72M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$14.3M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$31.8M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$35.0M, share buybacks n/a
ELOX balance sheet
- Jun 30, 2026: cash $62.0M, total assets $63.4M, total liabilities n/a, shareholders' equity $46.4M
- Mar 31, 2026: cash $6.36M, total assets $8.50M, total liabilities n/a, shareholders' equity −$7.58M
- Dec 31, 2025: cash $4.79M, total assets $5.27M, total liabilities $17.2M, shareholders' equity −$11.9M, long-term debt $0
- Dec 31, 2024: cash $111K, total assets $2.98M, total liabilities $27.3M, shareholders' equity −$24.3M, long-term debt $0
- Dec 31, 2023: cash $1.13M, total assets $1.71M, total liabilities $24.3M, shareholders' equity −$22.6M, long-term debt $1.61M
- Sep 30, 2023: cash $4.78M, total assets $6.04M, total liabilities $26.1M, shareholders' equity −$20.0M, long-term debt $2.62M
- Jun 30, 2023: cash $4.33M, total assets $5.99M, total liabilities $24.6M, shareholders' equity −$18.6M, long-term debt $3.33M
- Mar 31, 2023: cash $4.90M, total assets $7.20M, total liabilities $23.5M, shareholders' equity $16.3M, long-term debt $4.03M
What is ELOX's revenue?
ELOXX PHARMACEUTICALS INC reported $0 of revenue for the fiscal year ended December 2025.
Is ELOX profitable?
No. ELOXX PHARMACEUTICALS INC lost $6.00M in its latest fiscal year.